Sagent Pharmaceuticals and Actavis have signed an amendment to their manufacturing and supply agreement, providing an enhanced profit split in favor of Sagent, the addition of a zoledronic acid injection, 4 mg vial product, a modified termination date of December 31, 2014, and a one-time termination fee of $5 million payable to Sagent.   “Our mutually beneficial relationship with Actavis was an important contributor to the early development of our company,” said Jeffrey M. Yordon, pr...